Search
Roivant Sciences Ltd
ROIVAdd to Watchlist
28.560USD
+0.280+0.99%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
20.44BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+0.99%
5 Days
+2.62%
1 Month
+0.28%
6 Months
+38.51%
Year to Date
+31.61%
1 Year
+168.42%
TradingKey Stock Score of Roivant Sciences Ltd
Currency: USD Updated: 2026-05-08Key Insights
Roivant Sciences Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 49 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.91.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Roivant Sciences Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Roivant Sciences Ltd Highlights
StrengthsRisks
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Growing
The company is in a growing phase, with the latest annual income totaling USD 29.05M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -24.56, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 522.34M shares, decreasing 7.95% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.83K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.15.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
34.909
Target Price
+23.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Roivant Sciences Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Roivant Sciences Ltd Info
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Ticker SymbolROIV
CompanyRoivant Sciences Ltd
CEOVenker (Eric)
Websitehttp://roivant.com/
Related Instruments
-2.75%
-0.53%
-0.67%
+0.54%
+0.20%
-0.82%
+0.79%
-2.04%
+0.61%
-1.48%
-0.14%
+1.13%
+0.30%
-0.20%
-2.42%
+0.82%
0.00%
-1.05%
-0.65%
-0.86%Popular Instruments
92.193
-2.977 (-3.13%)
293.320
+5.817 (+2.02%)
215.200
+3.717 (+1.76%)
4714.280
+29.030 (+0.62%)
480.000
+16.095 (+3.47%)
1562.340
+222.380 (+16.60%)
746.810
+100.160 (+15.49%)
400.800
+2.723 (+0.68%)
80694.300
-81.200 (-0.10%)
428.350
+16.560 (+4.02%)
